Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca2+ axis

• Published in: mBio Vol. 14; no. 4; p. e0027223
• Main Authors: Zhang, Su, Zhou, Xuefeng, Ou, Min, Fu, Xiangdong, Lin, Qiao, Tao, Xiaoyu, Wang, Zhaoqin, Liu, Aimei, Li, Guobao, Xu, Yuzhong, Zhang, Guoliang
• Format: Journal Article
• Language: English
• Published: 1752 N St., N.W., Washington, DC American Society for Microbiology 31.08.2023
• Subjects: autophagy; berbamine; calcium; Mycobacterium tuberculosis; ROS
• ISSN: 2150-7511
• DOI: 10.1128/mbio.00272-23

Drug-resistant tuberculosis (TB) poses a major threat to global TB control; consequently, there is an urgent need to develop novel anti-TB drugs or strategies. Host-directed therapy (HDT) is emerging as an effective treatment strategy, especially for drug-resistant TB. This study evaluated the effects of berbamine (BBM), a bisbenzylisoquinoline alkaloid, on mycobacterial growth in macrophages. BBM inhibited intracellular Mycobacterium tuberculosis (Mtb) growth by promoting autophagy and silencing ATG5, partially abolishing the inhibitory effect. In addition, BBM increased intracellular reactive oxygen species (ROS), while the antioxidant N -acetyl-L-cysteine (NAC) abolished BBM-induced autophagy and the ability to inhibit Mtb survival. Furthermore, the increased intracellular Ca 2+ concentration induced by BBM was regulated by ROS, and BAPTA-AM, an intracellular Ca 2+ -chelating agent, could block ROS-mediated autophagy and Mtb clearance. Finally, BBM could inhibit the survival of drug-resistant Mtb. Collectively, these findings provide evidence that BBM, a Food and Drug Administration (FDA)–approved drug, could effectively clear drug-sensitive and -resistant Mtb through regulating ROS/Ca 2+ axis-mediated autophagy and has potential as an HDT candidate for TB therapy.